The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | Methods to access the clinical efficacy of mogamulizumab
Samuel Wilding, University of Manchester, Manchester, UK, explains the methods used to assess response to mogamulizumab in a Phase II study (NCT04745234) of mogamulizumab for cutaneous T-cell lymphoma (CTCL). Dermatological response was measured both prior to treatment and at peak response using the Modified Severity-Weighted Assessment Tool (mSWAT), which is obtained by multiplying the sum of body surface area affected by disease by a weighting factor for the severity of the disease. The hematological response was assessed using flow cytometry with markers for CD4, CD8, CD7 and CD26 to detect and quantify abnormal T-cells in peripheral blood. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
